Tag: temelimab
GeNeuro – Presentation of new data at ECTRIMS 2025 in Copenhagen showing the repair of neurodegenerative effects of HERV-W by Temelimab in a model of MS – 09/19/2024 at 6:30 p.m.
[ad_1] Geneva, Switzerland, September 19, 2024 – 6:30 PM CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company focused on addressing the drivers of neurodegenerative and autoimmune diseases,…
Phase 2 ProTEct-MS trial confirms safety of higher doses of temelimab and synergistic potential to treat neurodegeneration as an adjunct to anti-inflammatory treatment in multiple sclerosis – 03/21/2022 at 07:00 30
[ad_1] If you wish to receive all of the company’s financial communications in real time, you can register directly by email at the following address: [email protected] Holding of a webinar…